FDA approves first new class of schizophrenia treatment in more than 30 years

The FDA has approved Cobenfy, formerly known as KarXT, a muscarinic acetylcholine receptor agonist for the treatment of schizophrenia in adults.
Cobenfy (xanomeline-trospium, Bristol Myers Squibb) is the first antipsychotic medication for schizophrenia that targets cholinergic receptors rather than dopamine receptors, the FDA said. It represents the first new class of schizophrenia medication in decades.
“The approval of Cobenfy as a new class of medicine for the treatment of schizophrenia in adults is a significant step for patients and those who care for them, providing the first

The FDA has approved Cobenfy, formerly known as KarXT, a muscarinic acetylcholine receptor agonist for the treatment of schizophrenia in adults.
Cobenfy (xanomeline-trospium, Bristol Myers Squibb) is the first antipsychotic medication for schizophrenia that targets cholinergic receptors rather than dopamine receptors, the FDA said. It represents the first new class of schizophrenia medication in decades.
“The approval of Cobenfy as a new class of medicine for the treatment of schizophrenia in adults is a significant step for patients and those who care for them, providing the first